A registry to collect characteristics and outcomes from patients with solid tumors profiled with a next-generation sequencing test (WAYFIND-R)

Recruiting

• Conditions: Solid tumors (at any anatomic location, at any disease stage); ICD-O-3, ICD-10Adverse events and drug side effects; MedDRA, ATC

• Registration Number: DRKS00028931
• Lead Sponsor: F. Hoffmann-La Roche Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-05-25
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 15000

Inclusion Criteria

The registry population will include adult patients who are diagnosed with solid tumor cancers (at
any anatomical location) and at any stage of the disease. Both male and female patients will be
included in this registry.

Patients must meet the following criteria for enrolment in this registry:
- Patient is an adult (according to age of majority as defined by local regulations)
- Patient is currently diagnosed with any type of solid tumor cancer, at any stage of the
disease, at the enrolment date (informed consent date)
- Patient has undergone NGS testing, no longer than 3 months prior to the enrolment date,
irrespective of the availability of test results
- Informed consent has been obtained from the patient or legally authorized representative,
as per local regulations

Exclusion Criteria

Patients who meet the below exclusion criterion at the time of enrolment will not be enrolled in
this registry:
- Patient has a prior or current diagnosis of hematological malignancy

Study & Design

• Study Type: observational
• Study Design: Not specified